Cardiovascular diseases (CVD) are the leading cause of death globally, with coronary artery disease (CAD) as the most prevalent single cause. While previous studies, including our own, have highlighted the role of immunoglobulin G (IgG) glycosylation in CAD, the present study uniquely investigates the total plasma protein N-glycome as a potential biomarker of CAD. In this cross-sectional study, we analyzed total plasma protein N-glycans from three independent study populations using ultra-high-performance liquid chromatography with fluorescence detection (HILIC-UHPLC-FLR). Meta-analysis revealed significant glycan alterations in individuals with coronary atherosclerosis compared to individuals without CAD. Specifically, highly branched, complex N-glycans (triantennary and sialylated glycans) were significantly increased in CAD+ cases (Effect = 0.193, SE = 0.0761, padj = 0.0358), while monogalactosylated (Effect = -0.2464, SE = 0.0768, padj = 0.00814) and core fucosylated glycans (Effect = -0.2025, SE = 0.0818, padj = 0.0358) were significantly decreased. These changes suggest an increased presence of acute-phase glycoproteins and systemic inflammation in CAD+ individuals. Our findings demonstrate that CAD-associated glycomic alterations are not confined to IgG but are present across the total plasma protein glycome, providing a broader molecular view of disease-associated glycosylation changes. Future studies should explore the integration of plasma glycan signatures with other inflammatory and metabolic markers to refine CAD risk stratification strategies.
Trbojević et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: